Feed CLNN
CL

Clene Inc.

CLNN · NASDAQ

$3.57 -4.03% (-$0.15)
1M -14.80%
Market Cap $51.0M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 259.13x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Rev. growth 24.94%
EPS growth N/A
FCF growth N/A
Profitability
0 /100
Weak
Gross margin 110.15%
Net margin 20,059.90%
Op. margin 10,304.60%
Quality
0 /100
Poor
ROIC 104.55%
ROA 171.51%
Asset turnover 0.01x
Debt
43 /100
Moderate
Current ratio 3.07x
Int. coverage -10.15x
Debt/Equity N/A
Stability
24 /100
Unstable
Beta 0.95x
Rev. volatility 47.95%
EPS volatility 85.50%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CLNN
Online

O podjetju

Clene Inc. (CLNN) is a biotechnology company focusing on the development and commercialization of therapeutic therapies based on nanotechnologies for the treatment of neurodegenerative diseases. The company concentrates on developing therapeutic products that utilize nanocrystalline platforms to support nerve cell recovery and protection from degeneration. Clene Inc. is engaged in addressing diseases like amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. With the growing awareness of the need for neurodegenerative disease treatment, Clene Inc. has the potential for sustained growth. Clene Inc. (CLNN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for neurodegenerative diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Etherington

Employees

78

Headquarters

Salt Lake City

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

61d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.